New data from a second potency assay has been provided to the FDA and we have an upcoming meeting scheduled during March."Dr, Itescu also said that they have supplied more than enough data to support this second potency assay review.This is the last week in March so the meeting should be happening this week. If all goes well with this meeting Mesoblast should have a good idea about where they stand with the pediatric aGvHD decision. Meeting minutes may take another 30 days to be released but we are getting close, real close.Commercialization of pediatric aGvHD should begin a $150 million dollar annual revenue stream. That will be enough cashflow to keep things moving forward until the adult approval comes along which will add 5 times more revenue.This first approval means everything to Mesoblast, high risk/high reward. I'm in it to win!
LS
Aloha.
2024 Here we go again., page-285
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
-0.005(0.42%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.20 | $1.14 | $10.44M | 8.934M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 45750 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 1476 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.18 |
Change
-0.005 ( 0.31 %) |
||||
| Open | High | Low | Volume | ||
| $1.18 | $1.20 | $1.14 | 1465927 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| MSB (ASX) Chart |